Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Madrigal Pharmaceuticals, Inc. (MDGL) posted $958.40M in revenue for fiscal 2025 (up 432.1% year over year), with a net loss of $288.28M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. has grown revenue from $0 to $958.40M over the last 10 fiscal years. The most recent year was up 432.1%.
Net margin sits at -30.1%, up 228.5 points year over year on a 94.1% gross margin. It carries about $339.88M of total debt.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Madrigal Pharmaceuticals, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Madrigal Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $180.13M | $958.40M |
| Gross profit | — | — | — | — | — | — | — | — | $173.90M | $902.25M |
| Net income | $-26.39M | $-31.15M | $-32.81M | $-83.95M | $-202.24M | $-241.85M | $-295.35M | $-373.63M | $-465.89M | $-288.28M |
| Net margin | — | — | — | — | — | — | — | — | -258.6% | -30.1% |
Source: Madrigal Pharmaceuticals, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Madrigal Pharmaceuticals, Inc.: 3 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 33.6% over 4 years (17.1M → 22.8M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $339.9M of debt while last year's operating cash flow was negative ($-189.6M).
- Currently unprofitableThe latest fiscal year was a net loss (net margin -30.1%).
Explore 17 years of Madrigal Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MDGL in your portfolio →
Madrigal Pharmaceuticals, Inc. financial history by metric
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. — frequently asked questions
What is Madrigal Pharmaceuticals, Inc.'s revenue?
Madrigal Pharmaceuticals, Inc. (MDGL) reported revenue of $958.40M for fiscal year 2025, up 432.1% from the prior year, according to its SEC filings.
Is Madrigal Pharmaceuticals, Inc. profitable?
No — MDGL reported a net loss of $-288.28M in fiscal 2025.
What is MDGL's P/E ratio?
Madrigal Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Madrigal Pharmaceuticals, Inc. have?
As of fiscal year 2025, MDGL carried roughly $339.88M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Madrigal Pharmaceuticals, Inc.'s gross margin?
MDGL's gross margin was 94.1% in fiscal 2025 — gross profit of $902.25M on revenue of $958.40M.
What is Madrigal Pharmaceuticals, Inc.'s market cap?
Madrigal Pharmaceuticals, Inc. (MDGL) has a market capitalization of about $10.96B, based on the latest data in our nightly-refreshed cache.
When does Madrigal Pharmaceuticals, Inc.'s fiscal year end?
MDGL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Madrigal Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.